电邮这篇文章 Regional'naya programma lecheniya bol'nykh pervichno-generalizovannym i metastaticheskim rakom molochnoy zhelezy
- 作者: - -
- 期: 卷 9, 编号 3 (2007)
- 页面: 36-39
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26680
- ID: 26680
如何引用文章
全文:
详细
Обоснование расширения программы: • разработка одного из вариантов 2-й линии терапии больных первично-генерализованным (ПГРМЖ) и метастатическим раком молочной железы (МРМЖ) • оценка эффективности и переносимости монотерапии Келиксом в качестве второй линии терапии больных с ПГРМЖ и МРМЖ • рассмотрение возможности назначения Келикса в 1-й линии терапии у больных, имеющих факторы риска развития кардиологических осложнений • обобщение российского опыта применения Келикса для лечения больных МРМЖ.
参考
- Cameron R.B. Malignancies of the Breast. Chap. 53 in A Lange Clinical Manual - Practical Oncology 1st Edition. Norwalk: Appleton & Lange, 1994.
- Frei E, Teicher B.A, Holden S.A, Cathcart K.N, Wang Y.Y. Preclinical Studies and Clinical Correlation of the Effect of Alkylator Dose. Cancer Res 1988; 48:6417.
- Norton L, Hortobagyi G.N, Shpall E.J. Educational Book: Conceptual Issues in the High - Dose Chemotherapy of Breast Cancer. American Society of Clinical Oncology, 1995; 335–340.
- Papahadjopoulous D, Allen T.N, Gabizon A., et al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti-Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.
- Martin F.J, Gabizon A, Human Pharmacokinetics of Stealth Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.
- Uziely B, Jeffers S, Isacson R, et al. Liposomal Doxorubicin: Antitumor Activity and Unique Toxicities During Two Complementary Phase I Studies. J Clin Oncol, 1995; 13(7):1777–85.
- Keller, A. M.; Mennel, R. G.; Nabholtz, J. M.; Tendler, C. L.; et al.Phase III Trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) for the Treatment of Patients with Advanced Breast Cancer Who Have Failed a Prior Taxane - Containing Chemotherapy Regimen. Proc. Am. Soc. Clin. Oncol., (37th Ann. Mtg., ASCO, San Francisco, CA, USA, May 12-15, 2001), Vol. 20, Pt. 1, 2001, Abstr. No. 115.
- O'Brien N. Wigler, M. Inbar et al. , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil) vs conventional doxorubicin for first - line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9
- S-E Al-Batran et al.The clinical benefit of pegilated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br Jour Cancer, (2006), 1–6
- D.Lorusso et al. Pegylated liposomal doxorubicin - related palmar - plantar erythrodysesthesia ('hand - foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1–6.
